Content area
Full Text
In patients with rheumatoid arthritis (RA) who have failed tumour necrosis factor inhibitor (TNFi) treatment, cycling to another TNFi appears to be associated with greater healthcare costs than switching to a diseasemodifying antirheumatic drug with another mechanism of action (MOA), according to findings of a Sanofi- and Regeneron Pharmaceuticals-funded study published in Advances in Therapy.
Optum Research Database Commercial and Medicare Advantage claims data were used to assess treatment persistence and healthcare...